← back to search

Juan Politei

New York University · US
Area of research
Physiology · Rheumatology
Research interest
Research focused on Fabry disease and Enzyme replacement therapy, with related work in Disease, Workgroup, Data sharing. Notable publications include 'Fabry disease revisited: Management and treatment recommendations for adult patients', 'Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', and 'Cerebrovascular Involvement in Fabry Disease'.
h-index
citations
1,477
works
12
NIH funding
primary concept
email

Recent publications

Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community
Molecular Genetics and Metabolism 2023cited by 37position: middledoi
Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
Molecular Genetics and Metabolism Reports 2022cited by 17position: middledoi
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup
Journal of Medical Genetics 2020cited by 66position: middledoi
Enabling Global Clinical Collaborations on Identifiable Patient Data: The Minerva Initiative
Frontiers in Genetics 2019cited by 19position: middledoi
Fabry disease revisited: Management and treatment recommendations for adult patients
Molecular Genetics and Metabolism 2018cited by 637position: middledoi
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
Pediatric Nephrology 2018cited by 16position: firstdoi
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Kidney International 2016cited by 186position: middledoi
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Journal of Medical Genetics 2016cited by 147position: middledoi
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
CNS Neuroscience & Therapeutics 2016cited by 118position: firstdoi
Gastrointestinal involvement in Fabry disease. So important, yet often neglected
Clinical Genetics 2015cited by 53position: firstdoi
Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
Molecular Genetics and Metabolism Reports 2015cited by 25position: lastdoi
Cerebrovascular Involvement in Fabry Disease
Stroke 2014cited by 156position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David G. Warnock · University of Alabama at Birmingham5 papers (2015–2022)Eric Wallace · University of Alabama at Birmingham4 papers (2015–2018)Robert J. Hopkin · Ludwig-Maximilians-Universität München4 papers (2016–2023)Christoph Wanner · Smart Material (Germany)4 papers (2016–2023) · 4 papers (2016–2020)Michael Mauer · Dartmouth College3 papers (2016–2023)William R. Wilcox · Emory University3 papers (2018–2023) · 3 papers (2016–2023)Alessandro P. Burlina · New York University3 papers (2014–2018)Alberto Ortíz · Department of Public Health3 papers (2016–2023)Aleš Linhart · University Hospital in Motol3 papers (2016–2023)Daniel G. Bichet · Dalhousie University2 papers (2016–2020) · 2 papers (2015–2018) · 2 papers (2016–2018) · 2 papers (2015–2018)Frank Weidemann · Nova Medical (United States)2 papers (2018–2023)Han‐Wook Yoo · Ulsan College2 papers (2016–2020) · 2 papers (2015–2015)Max J. Hilz · Friedrich-Alexander-Universität Erlangen-Nürnberg2 papers (2014–2016)Nurcan Üçeyler · Apple (Israel)2 papers (2016–2022)